Search
Aleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.
Stanozolol
go.drugbank.com/drugs/DB06718ApprovedVet approvedStanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.
Products: อโซลอล 5 มก.Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigationalAchondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume ...
Cat dander extract
go.drugbank.com/drugs/DB13904ApprovedCat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.
LY-2183240
go.drugbank.com/drugs/DB17035ExperimentalLY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.[A253037]
Synonyms: 5-(biphenyl-4-ylmethyl)-n,n-dimethyl-1h-tetrazole-1-carboxamide, 1h-tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-n,n-dimethyl-Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...
Mixtures: PAVTIDE DISKUS 100 MCG INHALASYON ICIN TOZ, 60 DOZ, PAVTIDE DISKUS 250 MCG INHALASYON ICIN TOZ, 60 DOZProducts: CUTIVATE % 0,005 MERHEM, 15 GRAminomethylbenzoic acid
go.drugbank.com/drugs/DB13244ExperimentalAminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalEplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. … This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS